2-Methyl-3-p-cyanophenyl-2-buten | 34139-28-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Methyl-3-p-cyanophenyl-2-buten
• 英文别名: 4-(3-Methylbut-2-en-2-yl)benzonitrile；4-(3-methylbut-2-en-2-yl)benzonitrile
• CAS: 34139-28-1
• 化学式: C₁₂H₁₃N
• 分子量: 171.242
• InChiKey: NXPSEEHUNWZBTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-对氯苯基-3-甲基-2-丁烯 、 氰化亚铜 以 喹啉 为溶剂， 生成 2-Methyl-3-p-cyanophenyl-2-buten
  参考文献：
  名称：

  Chemistry of singlet oxygen. XII. Electronic effects on rate and products of the reaction with olefins

  摘要：

  DOI：

  10.1021/ja00749a032

文献信息

• Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
  申请人：Kamenecka M. Theodore

  公开号：US20070027321A1

  公开（公告）日：2007-02-01

  The present invention is directed to novel bipyridyl amine and ether compounds such as those of Formula (I): (I) (where R?1#191, R?2#191, R?3#191, X and Y are as defined herein) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel bipyridyl amine and/or ether compounds and/or compositions containing these compounds.

  本发明涉及新型的联吡啶胺和醚化合物，例如公式(I)中的化合物：(I) (其中R?1#191，R?2#191，R?3#191，X和Y如本文所定义)，这些化合物是mGluR5调节剂，可用于治疗或预防涉及mGluR5的疾病和病况，包括但不限于精神和情绪障碍，如精神分裂症、焦虑、抑郁、双相障碍和惊恐，以及治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍，如倒班工作引起的睡眠障碍和时差反应、药物成瘾、药物滥用、戒断综合征、肥胖症和其他疾病。本发明还涉及包含这些化合物的药物组合物。本发明还提供了通过给予这些新型联吡啶胺和/或醚化合物和/或含有这些化合物的组合物的有效量来治疗这些障碍和病况的方法。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：EP3204360B1

  公开（公告）日：2020-08-26
• Chemistry of singlet oxygen. XII. Electronic effects on rate and products of the reaction with olefins
  作者：Christopher S. Foote、Robert W. Denny

  DOI：10.1021/ja00749a032

  日期：1971.10